Bicalutamide, 150 mg 28 pcs

– Monotherapy or adjuvant therapy, in combination with a gonadotropin-releasing hormone (GnRH) analogue or surgical castration, of advanced prostate cancer;

– Treatment of locally advanced prostate cancer (T3-T4, any N, M0, T1-T2, N+, M0) as monotherapy or adjuvant therapy in combination with radical prostatectomy or radiotherapy;

The treatment of locally advanced nonmetastatic prostate cancer in cases where surgical castration or other drugs are not effective or are not acceptable

Active ingredient

Composition

Active substance:

bicalutamide 150 mg;

excipients:

Corn starch 107 mg,

croscarmellose sodium (primellose) 19.5 mg,

lactose monohydrate (milk sugar) 132.9 mg,

povidone 7.6 mg,

sodium stearyl fumarate 3 mg;

coating composition:

Opadray II white 12 mg, including: polyvinyl alcohol 4.8 mg, macrogol (polyethylene glycol) 2.424 mg, talc 1.776 mg, titanium dioxide 3 mg.

How to take, the dosage

Interaction

Special Instructions

Contraindications

Side effects

Overdose

Pregnancy use

Similarities